Company intelligence / Profile preview
Nippon Zenyaku Kogyo Co., Ltd.
Koriyama, Fukushima Prefecture, Japanzenyaku.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has several approved drugs including Rituximab (for liver transplant rejection), Liranaftate (for tinea corporis), and Sobuzoxane (for lymphoma). They also have TCN-032 in Phase 2 for influenza and Ismidenon in preclinical stage for memory disorders.
- Therapeutic areas
- ImmunologyDermatologyOncologyNeurologyInfectious Diseases
- Modalities
- Small molecule drugsMonoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Vetoquinol SA (joint venture: Vetoquinol-Zenoaq K.K.)NexvetNippon Biologicals Inc.Zinpro Animal Nutrition Japan K.K.Merial
Beyond the preview
Go deeper on Nippon Zenyaku Kogyo Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nippon Zenyaku Kogyo Co., Ltd..